Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Treasury Shares (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Treasury Shares for 4 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 26750.31% to $6.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.6 million, a 26750.31% increase, with the full-year FY2024 number at $24821.0, down 99.33% from a year prior.
  • Treasury Shares was $6.6 million for Q3 2025 at Century Therapeutics, up from $4.1 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $6.6 million in Q3 2025 to a low of $24685.0 in Q3 2024.
  • A 4-year average of $1.1 million and a median of $49465.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: crashed 90.5% in 2023, then soared 26750.31% in 2025.
  • Century Therapeutics' Treasury Shares stood at $193031.0 in 2022, then tumbled by 74.4% to $49416.0 in 2023, then crashed by 49.77% to $24821.0 in 2024, then skyrocketed by 26603.19% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Treasury Shares are $6.6 million (Q3 2025), $4.1 million (Q2 2025), and $4.7 million (Q1 2025).